$32
1.75%
Downside
Day's Volatility :3.23%
Upside
1.51%
45.34%
Downside
52 Weeks Volatility :47.62%
Upside
4.16%
Period | Mirum Pharmaceuticals Inc | |
---|---|---|
3 Months | 15.86% | |
6 Months | 21.53% | |
1 Year | 69.4% | |
3 Years | 33.89% |
Market Capitalization | 1.5B |
Book Value | $5.78 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -4.27 |
Wall Street Target Price | 54.7 |
Profit Margin | -113.45% |
Operating Margin TTM | -52.69% |
Return On Assets TTM | -13.64% |
Return On Equity TTM | -74.91% |
Revenue TTM | 144.7M |
Revenue Per Share TTM | 3.76 |
Quarterly Revenue Growth YOY | 154.1% |
Gross Profit TTM | 64.7M |
EBITDA | -104.2M |
Diluted Eps TTM | -4.27 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.47 |
EPS Estimate Next Year | -0.23 |
EPS Estimate Current Quarter | -0.65 |
EPS Estimate Next Quarter | -0.37 |
What analysts predicted
Upside of 70.94%
Sell
Neutral
Buy
Mirum Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|
Bvf Inc
Eventide Asset Management, LLC
NEA Management Company, LLC
BlackRock Inc
HHG PLC
Rock Springs Capital Management LP
Mirum Pharmaceuticals Inc’s price-to-earnings ratio stands at None
Read Moremirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.
Organization | Mirum Pharmaceuticals Inc |
Employees | 249 |
CEO | Mr. Christopher Peetz |
Industry | Health Technology |
Asymmetric Smart Alpha S&p 500 Etf
$32.00
-0.22%
Advisorshares Alpha Dna Equity Sentiment Etf
$32.00
-0.22%
Liberty Tripadvisor Hdg-b
$32.00
-0.22%
Tempo Automation Holdings Inc
$32.00
-0.22%
Falcon's Beyond Global Inc
$32.00
-0.22%
Jaguar Global Growth Corporation I
$32.00
-0.22%
Missfresh Ltd
$32.00
-0.22%
Shuaa Partners Acquisition Corp I
$32.00
-0.22%
Rose Hill Acquisition Corp
$32.00
-0.22%